Zykadia FDA Approval History
FDA Approved: Yes (First approved April 29, 2014)
Brand name: Zykadia
Generic name: ceritinib
Dosage form: Capsules
Company: Novartis Pharmaceuticals Corporation
Treatment for: Non-Small Cell Lung Cancer
Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Development timeline for Zykadia
| Date | Article |
|---|---|
| May 26, 2017 | Approval Novartis Receives FDA Approval for Expanded Use of Zykadia in First-Line ALK-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| Apr 29, 2014 | Approval FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
